(P017) Dosimetric Evaluation of Respiratory-Gated Radiotherapy for Left-Sided Breast Cancer

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The use of respiratory gating has resulted in small but statistically significant reductions in heart dose. Further studies are needed to understand the clinical implications of these differences.

Veronica Finnegan, MD, Varun Chowdhry, MD, Weidong Li, PhD, Katrina Stellingworth, CMD, Jeffrey Bogart, MD, Anna Shapiro, MD; SUNY Upstate; Massachusetts General Hospital

PURPOSE/OBJECTIVES: Adjuvant radiotherapy is associated with improvements in local control and survival in patients with breast cancer. As oncological outcomes have improved, there is a greater importance in preventing long-term toxicity from treatment. Technological advancements in radiotherapy delivery have the potential to allow better coverage of complex targets while reducing doses to normal structures. The use of four-dimensional computed tomography (4DCT) and respiratory gating has increased in clinical practice, but there is limited information regarding the utility of respiratory gating in breast cancer. The purpose of the study is to assess the dosimetric benefits of respiratory gating for patients receiving radiotherapy for left-sided breast cancer.

PATIENTS/METHODS: A total of 38 women with left-sided breast cancer were treated with respiratory gating between 2009 and 2013. All patients underwent 4DCT simulation using the Varian Real-Time Position Management respiratory gating system. The determination to use respiratory gating was at the discretion of the treating physician. For this study, maximum intensity projection (MIP) image sets containing images from all phases were also created. The original plans were copied to both the gated MIP and the all-phase MIP sets for dosimetric evaluations. Dose-volume histograms were calculated and compared. Doses to predefined heart and lung parameters were compared on two plans for each patient. Cardiac and pulmonary doses were compared for each patient using a two-sided paired difference test (t-test).

RESULTS: The use of respiratory gating resulted in statistically significant dose reductions to the heart on nearly all parameters evaluated. Mean whole heart dose was 368 cGy with gating and 389 cGy without gating (P < .001). V5 heart was 77% with gating and 84% without gating (P < .001). Max left anterior descending (LAD) dose was 3,990 cGy with gating and 4,264 cGy without gating (P = .009), and mean left ventricular dose was 511 cGy with gating and 549 cGy without gating (P < .001). There were trends toward a reduction of mean LAD dose (2,298 cGy with gating and 2,569 cGy without gating; P = .059) and max left ventricular dose (4,021 cGy with gating and 4,183 cGy without gating; P = .067). Statistically significant differences were not noted in any of the lung parameters tested (V5, V20, or V40).

CONCLUSION: The use of respiratory gating has resulted in small but statistically significant reductions in heart dose. Further studies are needed to understand the clinical implications of these differences.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content